Rhenman & Partners Asset Management AB cut its stake in Adamas Pharmaceuticals Inc (NASDAQ:ADMS) by 41.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 159,924 shares of the specialty pharmaceutical company’s stock after selling 113,669 shares during the quarter. Rhenman & Partners Asset Management AB owned approximately 0.58% of Adamas Pharmaceuticals worth $1,366,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ADMS. Macquarie Group Ltd. lifted its holdings in Adamas Pharmaceuticals by 36.2% in the third quarter. Macquarie Group Ltd. now owns 1,785,118 shares of the specialty pharmaceutical company’s stock valued at $35,738,000 after acquiring an additional 474,808 shares during the period. BlackRock Inc. lifted its holdings in Adamas Pharmaceuticals by 24.3% in the second quarter. BlackRock Inc. now owns 1,846,096 shares of the specialty pharmaceutical company’s stock valued at $47,684,000 after acquiring an additional 361,303 shares during the period. Marshall Wace LLP acquired a new position in Adamas Pharmaceuticals in the third quarter valued at approximately $4,316,000. Point72 Asset Management L.P. raised its stake in shares of Adamas Pharmaceuticals by 7.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,443,700 shares of the specialty pharmaceutical company’s stock worth $48,923,000 after buying an additional 171,585 shares during the period. Finally, Fosun International Ltd raised its stake in shares of Adamas Pharmaceuticals by 228.3% during the 4th quarter. Fosun International Ltd now owns 196,959 shares of the specialty pharmaceutical company’s stock worth $1,664,000 after buying an additional 136,959 shares during the period. 88.26% of the stock is owned by institutional investors.

Shares of ADMS stock opened at $8.97 on Monday. The company has a debt-to-equity ratio of 1.01, a current ratio of 8.95 and a quick ratio of 8.74. The company has a market cap of $245.24 million, a PE ratio of -2.26 and a beta of 1.41. Adamas Pharmaceuticals Inc has a 1-year low of $7.42 and a 1-year high of $36.63.

Several brokerages have recently weighed in on ADMS. Leerink Swann reaffirmed an “outperform” rating on shares of Adamas Pharmaceuticals in a research note on Friday, October 19th. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 1st. ValuEngine downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Cowen set a $30.00 target price on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 1st. Finally, Mizuho downgraded Adamas Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $75.00 to $18.00 in a research note on Monday, November 5th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $31.25.

ILLEGAL ACTIVITY NOTICE: “Rhenman & Partners Asset Management AB Has $1.37 Million Holdings in Adamas Pharmaceuticals Inc (ADMS)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.watchlistnews.com/rhenman-partners-asset-management-ab-has-1-37-million-holdings-in-adamas-pharmaceuticals-inc-adms/2813021.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Featured Story: Day Trading – Risk Worth the Reward?

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.